

# Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27<sup>Kip1</sup> in the acute promyelocytic leukemia cell line NB4

Christian Kardinal, Marc Dangers, Angelika Kardinal, Alexandra Koch, Dominique Tobias Brandt, Teruko Tamura, and Karl Welte

We have investigated the role of tyrosine phosphorylation of the cyclin-dependent kinase (cdk) inhibitor p27<sup>Kip1</sup> using the acute promyelocytic leukemia cell line NB4 together with granulocyte colony-stimulating factor (G-CSF). Short-term G-CSF stimulation resulted in a rapid tyrosine dephosphorylation of p27<sup>Kip1</sup> accompanied by a change in its binding preferences to cdks. On G-CSF stimulation, p27<sup>Kip1</sup> dissociated from cdk4 and

associated with cdk2. Binding assays with recombinant p27<sup>Kip1</sup> confirmed that tyrosine-phosphorylated p27<sup>Kip1</sup> preferentially bound to cdk4, whereas unphosphorylated protein preferentially associated with cdk2. In addition, studies with p27<sup>Kip1</sup> point mutations revealed a decisive role of Tyr88 and Tyr89 in binding to cdk4. Furthermore, phosphorylation of Tyr88 and Tyr89 was accompanied by strong nuclear translocation of p27<sup>Kip1</sup>.

Taken together, this report provides the first evidence that tyrosine phosphorylation of p27<sup>Kip1</sup> plays a crucial role in binding to cdks and its subcellular localization. Moreover, both effects are mediated by application of G-CSF. (Blood. 2006;107:1133-1140)

© 2006 by The American Society of Hematology

## Introduction

p27<sup>Kip1</sup> is an important regulator of the cell cycle, acting as a potent inhibitor of cyclin E- and A-dependent kinase cdk2, and as positive regulator of cyclin D-dependent kinases like cdk4.<sup>1</sup> However, recent data indicate that p27<sup>Kip1</sup> is not required for the formation of active cyclin D-cdk4 complexes, yet the complexes are more stable when bound to p27<sup>Kip1</sup>.<sup>2</sup> A major mechanism in the regulation of p27<sup>Kip1</sup> is phosphorylation on threonine and serine residues, whereas tyrosine phosphorylation remains elusive. Phosphorylation of Thr157 causes accumulation of p27<sup>Kip1</sup> in the cytoplasm and prevents G<sub>1</sub> arrest.<sup>3-5</sup> Thr187 and Ser10 are other phosphorylation sites essential for controlling its protein level.<sup>6-8</sup> A decrease in p27<sup>Kip1</sup> induces quiescent cells to proliferate, whereas an exit from the cell cycle is associated with up-regulation of p27<sup>Kip1</sup>.<sup>9</sup> It has been shown that p27<sup>Kip1</sup>-deficient mice are predisposed to the development of spontaneous tumors, and p27<sup>Kip1</sup> is considered a tumor suppressor.<sup>10,11</sup> Accumulating evidence suggests another role for p27<sup>Kip1</sup> in the regulation of cell migration independent of cyclin-cdk inhibition.<sup>12,13</sup> With reference to our own investigations, 2 independent studies reported granulocyte colony-stimulating factor (G-CSF)-mediated up-regulation of p27<sup>Kip1</sup>.<sup>14,15</sup> However, the role of p27<sup>Kip1</sup> in G-CSF signaling remains unclear.

We demonstrate here for the first time a biologic role of tyrosine phosphorylation on p27<sup>Kip1</sup>. Using the human acute promyelocytic leukemia cell line NB4 as a model for studying

cell cycle proteins in granulopoiesis, short-term treatment with G-CSF resulted in rapid tyrosine dephosphorylation of p27<sup>Kip1</sup>. In parallel, a switch in its binding preference to cyclin-dependent kinases was observed; a dramatic release from cdk4 coincided with a significantly increased binding to cdk2. Studies with p27<sup>Kip1</sup> point mutations support a decisive role of Tyr88 and Tyr89 in p27<sup>Kip1</sup>-binding to cdk4. In addition, our data provide evidence that phosphorylation of Tyr88 and Tyr89 contributes to subcellular localization of p27<sup>Kip1</sup>.

## Materials and methods

### Expression constructs

Site-directed mutagenesis of human p27<sup>Kip1</sup> cDNA was performed in the vector pCS2<sup>+</sup>-p27<sup>Kip1</sup> (gift from Nisar Malek, Hannover, Germany) with the QuickChange site-directed mutagenesis kit (Stratagene, Heidelberg, Germany). For transient expression of p27<sup>Kip1</sup> PolyFect Transfection Reagent (Qiagen, Hilden, Germany) was used. To express point-mutated p27<sup>Kip1</sup> as GST fusion protein, cDNA fragments (*Sma*I and *Xho*I restricted) containing the point mutations were subcloned into *Sma*I and *Xho*I-restricted plasmid pGEX-5x-3-p27<sup>Kip1</sup> wild type (wt; gift from Nisar Malek). GST fusion proteins were expressed in DH5 $\alpha$  and TKX1 (Stratagene) *Escherichia coli* strains.

From the Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover (MHH), Hannover, Germany; Nephrologie, MHH, Hannover, Germany; Lehrstuhl für Angewandte Physik, Universität München, München, Germany; Institut für Biochemie, MHH, Hannover, Germany; and Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Germany.

Supported by grant SFB566 of the Deutsche Forschungsgemeinschaft (DFG). C.K. conceived, designed, and performed research and wrote paper; M.D. performed research and wrote paper; A. Kardinal performed research; A. Koch provided analytical tools; D.T.B. reviewed and discussed research; T.T. designed and discussed research; and K.W. was involved in the conception and discussion of the research.

The online version of the article contains a data supplement.

Submitted May 2, 2005; accepted September 20, 2005. Prepublished online as *Blood* First Edition Paper, September 29, 2005; DOI 10.1182/blood-2005-05-1771.

**Reprints:** Christian Kardinal, Pädiatrische Hämatologie und Onkologie, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; e-mail: kardinal.christian@mh-hannover.de.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2006 by The American Society of Hematology

## Antibodies

For precipitation, blotting, and immunostaining the following antibodies were used: polyclonal antibodies to cdk2 (06-505, Upstate Biotechnology, Hamburg, Germany), cdk4 (06-139, Upstate Biotechnology), cyclin D (sc-753, Santa Cruz Biotechnology, Heidelberg, Germany), Grb2 (sc-255, Santa Cruz Biotechnology), p21<sup>Cip1</sup> (sc-397, Santa Cruz Biotechnology), p27<sup>Kip1</sup> (sc-528, Santa Cruz Biotechnology, used generally with the exception of experiments shown in Figure 2C, Figure 3E, and Figure 4A), p85 (06-505, Upstate Biotechnology), PU.1 (sc-352, Santa Cruz Biotechnology), and monoclonal antibodies to Abl (8E9, BD Biosciences, Heidelberg, Germany), BrdU (347583, BD Biosciences), cyclin E (554182, BD Biosciences), G-CSF receptor (gift from M. Hadam, Hannover, Germany), Grb2 (G16729, BD Biosciences), p27<sup>Kip1</sup> (610242, BD Biosciences, used in experiments shown in Figure 2C, Figure 3E, and Figure 4A), antiphosphotyrosine pY99 (sc-7020, Santa Cruz Biotechnology), and Src (05-184, Upstate Biotechnology).

## Cell culture, stimulation, and preparation of cell lysates

The human acute promyelocytic leukemia cell line NB4 (DMSZ, Braunschweig, Germany, all other cells from American Type Culture Collection, Rockville, MD), the human myelomonocytic leukemia cell line U937, human promyelocytic leukemia cells HL60, and the human chronic myelogenous leukemia cell line K562 were cultured in RPMI 1640 supplemented with 10% FBS, 20 mM L-glutamine, 1000 U/L penicillin, and 100 mg/L streptomycin. Human embryo renal cortical cells HEK293 and mouse embryo fibroblast cells NIH/3T3 were cultured in DMEM with 10% FBS. For stimulation with G-CSF (50 ng/mL; Amgen, Thousand Oaks, CA) or treatment with vanadate (100  $\mu$ M),  $8 \times 10^6$  NB4 cells were seeded into culture flasks in 20 mL medium and were incubated for 24 hours at 37°C. At the time points indicated, stimulation was stopped by pouring the cell suspension into ice-cold PBS supplemented with 100  $\mu$ M sodium orthovanadate (Na<sub>3</sub>VO<sub>4</sub>). Cell extracts were prepared by solubilization in RIPA buffer (20 mM Tris HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitors (10  $\mu$ g/mL aprotinin, 5  $\mu$ g/mL phenylmethylsulfonyl fluoride, 4  $\mu$ g/mL leupeptin, 10  $\mu$ g/mL antipain, 4  $\mu$ g/mL pepstatin, 50 mM NaF, and 2 mM Na<sub>3</sub>VO<sub>4</sub>).

## Subcellular fractionation

NB4 cells were washed once with PBS and once with hypotonic lysis buffer (10 mM Tris HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 10 mM KCl, 2 mM MgCl<sub>2</sub>, 1 mM DTT). The cell pellet was resuspended in an equivalent volume hypotonic lysis buffer containing protease and phosphatase inhibitors, transferred into an ice-cooled Dounce homogenizer, incubated 20 minutes at 4°C, and homogenized by 15 strokes with the homogenizer. After centrifugation of the cell extract at 1600g, the supernatant fraction (cytosolic proteins) was separated from the pellet fraction (nuclear proteins), and the pellet fraction was lysed in RIPA buffer.

## Immunoprecipitations and Western blotting

Immunoprecipitations (IPs) from 500  $\mu$ g total cell lysate were performed by incubation in IP buffer (20 mM Tris HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 5% glycerol, 0.5% Tween 20) containing protease and phosphatase inhibitors, 2  $\mu$ g rabbit polyclonal or mouse monoclonal antibody, and protein A-Sepharose or protein G-Sepharose overnight at 4°C. The pellets were washed 3 times with RIPA buffer, resuspended in sample buffer, and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). To dephosphorylate tyrosine residues of precipitated p27<sup>Kip1</sup>, the washed immunocomplexes were incubated with 10 U LAR protein tyrosine phosphatase (LAR-PTP; New England Biolabs, Frankfurt/Main, Germany) for 30 minutes at 30°C as described in the manufacturer's protocol. Antibodies used for precipitation and blotting are described in detail (see "Antibodies"). For redetection with another antibody the previous antibody was removed completely from the blot by incubation in blot-stripping buffer (60 mM Tris, pH 6.8, 2% SDS, 0.1%  $\beta$ -mercaptoethanol) for 20 minutes at 50°C while shaking gently.

## Isoelectric focusing

For isoelectric focusing (IEF) of immunocomplexes, the precipitates were washed 3 times with 1% Triton X-100/Tris-buffered saline (20 mM Tris, pH 7.5, 150 mM NaCl), and lysed in 50  $\mu$ L IEF lysis buffer (6 M urea, 2 M thiourea, 4% CHAPS, 2% DTT) for 20 minutes at 4°C. Thereafter, proteins from the lysate were purified with Micro Bio-Spin R6 (Bio-Rad, Munich, Germany) chromatography columns that had been buffered with rehydration solution (6 M urea, 2 M thiourea, 2% CHAPS, 0.4% DTT). The eluates were diluted with 250  $\mu$ L rehydration solution, and the final volume was supplemented with 0.5% IPG buffer (pH 3-10 NL). Loading of the samples onto immobilized drystrip gels (pH 3-10 NL, 13 cm) and focusing in an IPGphor IEF system (Pharmacia, Freiburg, Germany) were performed following the manufacturer's instructions. Analysis of the separated proteins was accomplished on a Macintosh computer using the public domain National Institutes of Health Image software (<http://rsb.info.nih.gov/nih-image/>).

## Phosphoamino acid analysis

NB4 cells ( $4 \times 10^6/10$  mL) were seeded into culture flasks (see "Cell culture, stimulation, and preparation of cell lysates") and were incubated overnight. Thereafter, the cells were washed once with phosphate-free medium, preincubated in 5 mL phosphate-free medium (3% FCS, 20 mM L-glutamine, 1000 U/L penicillin, 100 mg/L streptomycin) for 1 hour, and labeled with 1 mCi (37 MBq)/mL [<sup>32</sup>P] phosphoric acid for 4 hours. Cell extracts and anti-p27<sup>Kip1</sup> immunoprecipitations were prepared as depicted above. Phosphoamino acid analysis was performed as described previously.<sup>16</sup>

## In vitro binding of p27<sup>Kip1</sup>

In vitro binding of p27<sup>Kip1</sup> to cdk2 and cdk4 was carried out with 500  $\mu$ g total cell lysate using 2  $\times$  lysis buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 200 mM NaCl, 2% NP-40, 10% glycerol). The protein complexes were precipitated by incubation of 1  $\mu$ g GST fusion protein with glutathione-Sepharose beads in binding buffer (25 mM Tris-HCl, pH 7.5, 1 mM DTT, 30 mM MgCl<sub>2</sub>, 40 mM NaCl, 0.5% NP-40, protease and phosphatase inhibitors as described) for 15 minutes at 4°C. Precipitates were washed 3 times with RIPA buffer, resuspended in sample buffer, and analyzed by Western blotting.

## Immunofluorescence

At 48 hours after transient transfection, cells grown on glass coverslips were incubated with BrdU (10  $\mu$ M; Sigma, Munich, Germany) for 4 hours. Thereafter, cells were rinsed in PBS and fixed in 4% paraformaldehyde at room temperature for 15 minutes. Coverslips were stored in PBS at 4°C until stained. Cells were permeabilized for 20 minutes in 0.2% Triton X100/PBS and rinsed 3 times in PBS. After the cells were blocked in antibody dilution buffer (3% BSA, 0.1% Tween 20/PBS) for 15 minutes, they were incubated for 1 hour with anti-p27<sup>Kip1</sup> antibody (monoclonal, see "Antibodies") at room temperature. The coverslips were rinsed 3 times in PBS and incubated with rhodamine-conjugated anti-mouse IgG (H+L) antibody (715-295-150, Jackson ImmunoResearch, Hamburg, Germany) for 30 minutes at room temperature. The coverslips were rinsed 3 times in PBS and the cells were treated with DNase I (50  $\mu$ g/mL in PBS) for 1 hour at 37°C. After washing 3 times in PBS the coverslips were incubated in antibody dilution buffer supplemented with anti-human IgG1 blocking antibody (1 mg/mL; gift from M. Hadam, Hannover, Germany) and anti-BrdU-FITC antibody for 1 hour at room temperature. The coverslips were rinsed 3 times in PBS and mounted on glass slides. Images were obtained on a Nikon Eclipse TE 300 microscope (Düsseldorf, Germany) with a  $\times 20$  objective using a Spot 2 camera (Diagnostic Instruments, Ismaning/Munich, Germany) and Metamorph 4.0 Software (Universal Imaging, Ismaning/Munich, Germany).

## Hoechst-33342 dye staining

Morphologic changes of apoptotic cells were determined by fluorescence microscopy. Therefore, cells on coverslips immunostained with anti-p27<sup>Kip1</sup>

antibody (see “Immunofluorescence”) were rinsed 3 times in PBS, incubated in 0.5 mM Hoechst-33342 dye (Sigma) for 10 minutes at room temperature, and visualized under a fluorescence microscope (see “Immunofluorescence”). The cells with nuclei containing condensed chromatin or cells with fragmented nuclei were defined as apoptotic cells.

## Results

### p27<sup>Kip1</sup> interacts with the G-CSF receptor via Grb2

It has been reported that Grb2 docks to the G-CSF receptor<sup>17,18</sup> and is associated with p27<sup>Kip1</sup>.<sup>19</sup> To examine the role of p27<sup>Kip1</sup> and Grb2 in G-CSF–mediated signaling we performed an anti-G-CSF receptor immunoprecipitation from total lysate of unstimulated and G-CSF–stimulated NB4 cells. Detection of the Western blot with antibodies to p27<sup>Kip1</sup> (for control of specificity, see Figure S1A, available on the *Blood* website; see the Supplemental Figure link at the top of the online article) and Grb2 showed that both proteins were associated with the receptor (Figure 1A left panel). In this analysis 3 major G-CSF receptor isotypes (arrows) were detected, representing different posttranslational modifications. Furthermore, on stimulation with G-CSF for 60 minutes, stronger signals of p27<sup>Kip1</sup> and Grb2, as compared to unstimulated cells, indicate an enhanced interaction of both proteins with the receptor. In addition, Grb2 immunoprecipitations confirm an interaction of p27<sup>Kip1</sup> with the G-CSF receptor via Grb2 (Figure 1A middle panel). Again, on G-CSF stimulation stronger signals of p27<sup>Kip1</sup> and the G-CSF receptor argue for an increased interaction of the proteins, as compared to unstimulated cells. To exclude in these immunoprecipitations

the possibility of unspecific binding we performed as a negative control immunoprecipitations with an irrelevant anti-human IgG antibody. As expected, no unspecific binding to our investigated proteins was detected (Figure 1A, right panel).

### p27<sup>Kip1</sup> is tyrosine phosphorylated in NB4 cells

Until now, only phosphorylation of p27<sup>Kip1</sup> on threonine and serine residues has been shown to play a physiologic role, whereas tyrosine phosphorylation remains elusive. To investigate tyrosine phosphorylation of p27<sup>Kip1</sup> we first performed immunoprecipitations with p27<sup>Kip1</sup> from the lysate of different cell lines. Detection of the corresponding Western blots using a monoclonal antibody to phosphotyrosine revealed strong tyrosine phosphorylation in the cell lines NB4 and U937 (Figure 1B). To verify tyrosine phosphorylation of p27<sup>Kip1</sup> we incubated p27<sup>Kip1</sup> immunoprecipitates with LAR-PTP and probed the Western blots with antiphosphotyrosine antibody. As expected, incubation with LAR-PTP completely removed tyrosine phosphorylation (Figure 1C). In addition, we performed an *in vivo* labeling of cellular p27<sup>Kip1</sup> with [<sup>32</sup>P] phosphoric acid. Again, we observed a distinct tyrosine phosphorylation of p27<sup>Kip1</sup> (Figure S1C). The intensities of phosphoserine, phosphothreonine, and phosphotyrosine approximately mirror the respective occurrence of the residues in the molecule.


### G-CSF induces tyrosine dephosphorylation of p27<sup>Kip1</sup>

To examine the effect of G-CSF on p27<sup>Kip1</sup> tyrosine phosphorylation in NB4 cells, we stimulated cells with G-CSF and harvested them at different time points. Grb2 and p27<sup>Kip1</sup> immunoprecipitates performed from the lysate of unstimulated cells and probed with antiphosphotyrosine antibody showed a broad band in the molecular weight region of p27<sup>Kip1</sup>. To our surprise, however, on stimulation the phosphotyrosine signal rather declined from 15 minutes onward (Figure 2A).


To confirm the G-CSF–mediated tyrosine dephosphorylation of p27<sup>Kip1</sup> we performed antiphosphotyrosine immunoprecipitations and probed them with anti-p27<sup>Kip1</sup> antibody. The longer the cells were stimulated with G-CSF the less p27<sup>Kip1</sup> was precipitable with the antibody (Figure 2B). As a p27<sup>Kip1</sup>-independent control the Western blot was detected with an antibody to the PI 3-kinase subunit p85, which is also implicated in G-CSF–mediated signaling.<sup>20</sup> However, tyrosine phosphorylation of p85 remained unaffected by G-CSF stimulation in NB4 cells.

To further strengthen these findings, we investigated whether sodium orthovanadate, a potent inhibitor of phosphotyrosine-specific phosphatases, alters G-CSF–mediated tyrosine dephosphorylation of p27<sup>Kip1</sup>. Therefore, we stimulated NB4 cells in parallel with vanadate and G-CSF and performed p27<sup>Kip1</sup> immunoprecipitations. As shown in Figure 2C, G-CSF–mediated tyrosine dephosphorylation of p27<sup>Kip1</sup> was significantly reduced by vanadate.

The G-CSF–mediated phosphotyrosine shift was analyzed in more detail by IEF of p27<sup>Kip1</sup> immunoprecipitates using a nonlinear gradient pH 3 to 10 with increased resolution between pH 5 to 7. IEF of the immunoprecipitate from the lysate of untreated NB4 cells resulted in 4 p27<sup>Kip1</sup> spots (Figure 2C, top panel). Densitometric quantitation confirmed 2 equally dominant spots (spots 1 and 3). G-CSF treatment of the cells for 60 minutes resulted in most p27<sup>Kip1</sup> migrating as spot 1. The intensity of the other forms, including spot 3, was significantly diminished (Figure 2C, middle panel). Due to a methodologic restriction of IEF, tyrosine phosphorylation could not be assessed on the blots. However, because an increase of the isoelectric point usually is accompanied by a



**Figure 1. p27<sup>Kip1</sup> interacts with Grb2 and G-CSF receptor and is tyrosine-phosphorylated in NB4 cells.** (A) Lysates of NB4 cells untreated or stimulated with G-CSF for 60 minutes were precipitated with antibody to the G-CSF receptor or Grb2 and probed as indicated. Control immunoprecipitations with an antibody to human IgG excluded the possibility of unspecific binding. (B) Lysates of different cell lines were precipitated with anti-p27<sup>Kip1</sup> and the Western blot was probed as indicated. (C) Immunoprecipitated p27<sup>Kip1</sup> from NB4 cells was incubated with 10 U LAR-PTP for 30 minutes at 30°C. Tyrosine phosphorylation of LAR-treated p27<sup>Kip1</sup> was compared to untreated p27<sup>Kip1</sup>.



**Figure 2. Application of G-CSF induces tyrosine dephosphorylation of p27<sup>Kip1</sup>.** (A) NB4 cells were stimulated with G-CSF and harvested at different time points. Grb2 and p27<sup>Kip1</sup> immunoprecipitations were performed and detected with antibodies as indicated. (B) Lysates of stimulated NB4 cells were precipitated with antiphosphotyrosine antibody and detected with anti-p27<sup>Kip1</sup> and anti-PI 3-kinase (p85) antibody. (C) NB4 cells were stimulated with G-CSF or G-CSF/vanadate for 60 minutes. p27<sup>Kip1</sup> immunoprecipitations were performed and detected with antibodies as indicated. (D) p27<sup>Kip1</sup> immunoprecipitate (incubated with or without 10 U LAR-PTP) from NB4 lysate of untreated cells or cells stimulated with G-CSF for 60 minutes was separated by IEF using a nonlinear gradient pH 3 to 10 and probed with anti-p27<sup>Kip1</sup> antibody.


decrease in phosphorylation, dephosphorylation of p27<sup>Kip1</sup> after application of G-CSF must be considered the most likely explanation. Therefore, we incubated p27<sup>Kip1</sup> immunoprecipitate from lysate of NB4 cells with LAR-PTP. Similar to G-CSF treatment, IEF of the phosphatase-treated immunoprecipitate resulted in most of p27<sup>Kip1</sup> migrating as spot 1, whereas the intensity of the other 3 forms was significantly diminished (Figure 2C, bottom panel). Taken together, these data show that treatment of the promyelocytic cell line NB4 with G-CSF for 2 hours resulted in a strong decline of p27<sup>Kip1</sup> tyrosine phosphorylation. In addition, IEF confirmed a significant switch in p27<sup>Kip1</sup> modification induced by G-CSF.

#### Phosphorylation of p27<sup>Kip1</sup> on tyrosine residues 88 and 89 modulates binding preference to cdk2

Considering the interaction of p27<sup>Kip1</sup> with cyclin E-cdk2 and cyclin D-cdk4 protein complexes we examined the binding of p27<sup>Kip1</sup> to cdk2 and cdk4 on G-CSF stimulation. Thus, we performed immunoprecipitations from the lysate of stimulated NB4 cells using anti-cdk2 and anti-cdk4 antibodies. Detection of

the cdk2 immunoprecipitates with anti-p27<sup>Kip1</sup> antibody demonstrated an elevated binding of p27<sup>Kip1</sup> to cdk2, which could be visualized from 30 minutes after stimulation with G-CSF. In contrast, reduced binding to cdk4 was detectable as early as 15 minutes after stimulation (Figure 3A).

To verify that tyrosine phosphorylation of p27<sup>Kip1</sup> plays a role in cellular signal transduction we tested binding of p27<sup>Kip1</sup> to cdk4 by incubation of p27<sup>Kip1</sup> immunoprecipitate with LAR-PTP and probed the Western blot with anti-cdk4. Immunoprecipitated p27<sup>Kip1</sup> incubated with LAR-PTP was in weak association with cdk4, whereas untreated protein largely bound to cdk4 (Figure 3B). To confirm the binding preference and to determine the corresponding tyrosine phosphorylation sites, we investigated the in vitro binding of GST-p27<sup>Kip1</sup> fusion proteins to cdk2 and cdk4. Hence, fusion protein was expressed in *E coli* strains DH5 $\alpha$  and TKX1. TKX1 allows for specific tyrosine phosphorylation of the fusion protein by induction of a tyrosine kinase gene. Within p27<sup>Kip1</sup>, there are 3 tyrosine residues at positions 74, 88, and 89 (Tyr74, Tyr88 and Tyr89), whereas the GST part of the fusion protein contains no tyrosine residue. Pull-down assays with GST-p27<sup>Kip1</sup> fusion proteins incubated in NB4 lysate show that unphosphorylated (pTyr<sup>-</sup>) wt p27<sup>Kip1</sup> preferentially bound to cdk2 (Figure 3C, upper left panel). In contrast, phosphorylated (pTyr<sup>+</sup>) p27<sup>Kip1</sup> wt preferentially associated with cdk4 (Figure 3C, bottom left panel).



**Figure 3. Tyrosine dephosphorylation of p27<sup>Kip1</sup> alters the binding to cdk2.** (A) NB4 cells were stimulated with G-CSF and harvested at different time points. Immunoprecipitations with cdk2 and cdk4 were performed and probed by Western blotting with antibodies as indicated. A total of 50 or 100  $\mu$ g lysate from untreated cells was also loaded as a control. (B) p27<sup>Kip1</sup> immunoprecipitate from NB4 lysate was incubated with LAR-PTP. The Western blot was probed with antibodies to cdk4 and p27<sup>Kip1</sup>. Binding of cdk4 to p27<sup>Kip1</sup> (treated with LAR-PTP or untreated) was detected. (C) GST-p27<sup>Kip1</sup> fusion proteins (p27<sup>Kip1</sup> wt and tyrosine to phenylalanine mutations Y74F, Y88F, Y89F, Y88/89F, Y74/88/89F) were expressed in *E coli* strains DH5 $\alpha$  (pTyr<sup>-</sup>: not tyrosine-phosphorylated) and TKX1 (pTyr<sup>+</sup>: tyrosine-phosphorylated). After incubation of the fusion proteins in NB4 lysate together with GSH agarose for 15 minutes at 4°C, the protein complexes were separated by PAGE and blotted and binding of the p27<sup>Kip1</sup> wt or point mutations with cdk2 and cdk4 was evaluated by detection with the appropriate antibodies. (D) Plasmids containing p27<sup>Kip1</sup> wt sequence as well as point mutations (with or without Abl-PP sequence) were transiently expressed in NIH/3T3 cells. p27<sup>Kip1</sup> immunoprecipitations were performed and probed with antibodies as indicated. As control for Abl-PP expression, a total of 100  $\mu$ g lysate was also detected. (E) Lysate from transfected NIH/3T3 cells was immunoprecipitated and probed as indicated.

To determine the tyrosine residues responsible for the binding preference to cdk2 and cdk4, respectively, we performed assays with tyrosine to phenylalanine point mutations (Y74F, Y88F, Y89F, Y88/89F, and Y74/88/89F). Detection of Western blots demonstrated that binding to cdk2 was unaffected by any point mutation (Figure 3C, top panels). In all cases the unphosphorylated protein (pTyr<sup>-</sup>) displayed a stronger binding to cdk2 when compared to the corresponding phosphorylated (pTyr<sup>+</sup>) version. In contrast, interaction of GST-p27<sup>Kip1</sup> with cdk4 was significantly influenced by mutations of tyrosine residues. Detection of Western blots with anti-cdk4 antibody (Figure 3C, bottom panels) showed that the Y74F mutation, compared to the wild-type protein, induced no change in binding to cdk4, whereas Y88F and Y89F mutations blocked preferential binding of tyrosine-phosphorylated (pTyr<sup>+</sup>) protein to cdk4. In contrast to wt and Y74F proteins unphosphorylated (pTyr<sup>-</sup>) Y88F and Y89F mutations displayed a stronger binding to cdk4. Most notably, double mutation of residues 88 and 89 (Y88/89F) resulted in a general blockade of binding to cdk4, illustrating that both residues are essential for binding. As a consequence, the triple mutant (Y74/88/89F) also displayed general failure of binding to cdk4.

Considering the interaction of p27<sup>Kip1</sup> with cyclin E-cdk2 and cyclin D-cdk4 protein complexes, we investigated the *in vitro* binding of GST-p27<sup>Kip1</sup> wt to cyclin E and cyclin D. However, neither unphosphorylated nor tyrosine-phosphorylated p27<sup>Kip1</sup> showed interaction with cyclin E or cyclin D (Figure S1B).

To examine the binding preference of tyrosine-phosphorylated p27<sup>Kip1</sup> to cdk2 and cdk4 *in vivo* we transiently expressed wt, Y74F, Y88/89F, and Y74/88/89F p27<sup>Kip1</sup> in NIH/3T3 fibroblasts. To ensure tyrosine phosphorylation of transient p27<sup>Kip1</sup> we cotransfected the cells with a plasmid containing the sequence of constitutive active c-Abl kinase (Abl-PP).<sup>21</sup> To confirm Abl-PP-induced tyrosine phosphorylation of p27<sup>Kip1</sup> we performed from lysate of transfected cells immunoprecipitates to p27<sup>Kip1</sup> and detected the corresponding Western blot with antiphosphotyrosine antibody. As expected, with the exception of the mutant lacking all tyrosine residues (Y74/88/89F) cotransfection of Abl-PP resulted in tyrosine phosphorylation of p27<sup>Kip1</sup>, whereas in the absence of Abl-PP no tyrosine phosphorylation on wt p27<sup>Kip1</sup> was detectable (Figure 3D). In cells not cotransfected with Abl-PP immunoprecipitated cdk2 was found predominantly in association with transient p27<sup>Kip1</sup>. In contrast, immunoprecipitated cdk4 preferentially bound to p27<sup>Kip1</sup> phosphorylated by Abl-PP (Figure 3E). In summary, these results mirror the *in vitro* data presented and support the importance of p27<sup>Kip1</sup> tyrosine phosphorylation.

#### Tyrosine phosphorylation of p27<sup>Kip1</sup> contributes to nuclear translocation

To investigate the biologic role of p27<sup>Kip1</sup> tyrosine phosphorylation, we examined subcellular localization of transiently expressed p27<sup>Kip1</sup> by immunostains with antibody to p27<sup>Kip1</sup>. Fluorescence microscopy showed equal distribution of unphosphorylated wt p27<sup>Kip1</sup> in the cytoplasm and nucleus (Figure 4A, top left panel), whereas tyrosine phosphorylation of wt and Y74F p27<sup>Kip1</sup> induced by Abl-PP cotransfection resulted in strong nuclear translocation. Y88/89F and Y74/88/89F p27<sup>Kip1</sup> cotransfected with Abl-PP failed to translocate to the nucleus (Figure 4A, top panels). To investigate proliferation we incubated transfected cells with BrdU for 4 hours. In all transfection assays the overall number of BrdU<sup>+</sup> cells and efficiency of p27<sup>Kip1</sup> expression were comparable. Immunostaining with anti-BrdU antibody showed that p27<sup>Kip1</sup>-overexpressing cells did not incorporate BrdU. In contrast, cells with lack of transient

p27<sup>Kip1</sup> displayed BrdU incorporation (Figure 4A, middle and bottom panels).

To rule out apoptosis as an explanation for failed active cycling of transiently expressing cells, we stained nuclei with Hoechst-33342 dye. However, cells expressing transient protein did not significantly display morphologic features of apoptosis, such as cell shrinkage, chromatin condensation, and nuclear pyknosis (Table 1).

Taken together, these findings show that phosphorylation of both Tyr88 and Tyr89 modulates nuclear translocation. However, overexpression of p27<sup>Kip1</sup> independently of tyrosine phosphorylation resulted in a general blockade of proliferation, whereas apoptosis was not affected.

To relate our data on NIH/3T3 fibroblasts to NB4 cells, we examined subcellular distribution of p27<sup>Kip1</sup> in untreated and G-CSF-stimulated NB4 cells by cell fractionation. Western blotting showed (Figure 4B) that p27<sup>Kip1</sup> was equally distributed between cytosolic fraction and nuclear fraction in untreated cells. On stimulation with G-CSF for 60 minutes, however, the p27<sup>Kip1</sup> signal in the nuclear fraction strongly declined. Because our data document G-CSF-mediated tyrosine dephosphorylation of p27<sup>Kip1</sup>, nuclear translocation of tyrosine-phosphorylated protein must be considered the most likely explanation.


## Discussion

In this study we investigated the cyclin-dependent kinase (cdk) inhibitor p27<sup>Kip1</sup> in G-CSF receptor-mediated signaling using the acute promyelocytic leukemia cell line NB4. To examine the link between receptor and p27<sup>Kip1</sup> in NB4, we analyzed the role of growth factor receptor-bound protein 2 (Grb2). It has been reported that Grb2 docks to the G-CSF receptor<sup>17,18</sup> and is associated with p27<sup>Kip1</sup>.<sup>19</sup> In this regard, our data suggest that p27<sup>Kip1</sup> contributes to G-CSF-mediated signaling via interaction with Grb2.

A major mechanism in the regulation of p27<sup>Kip1</sup> is phosphorylation on threonine and serine residues, whereas tyrosine phosphorylation remains elusive. Thus, we analyzed p27<sup>Kip1</sup> tyrosine phosphorylation of different cell lines and detected strong phosphorylation in G-CSF receptor-expressing leukemic cell lines NB4 and U937. Furthermore, in both cell lines a rapid tyrosine dephosphorylation of p27<sup>Kip1</sup> was observed on G-CSF stimulation (for U937 data not shown). The phosphotyrosine shift was analyzed in more detail by IEF of p27<sup>Kip1</sup> immunoprecipitates. IEF of p27<sup>Kip1</sup> from the lysate of untreated cells resulted in 4 spots. The intensity of 3 spots, representing differently modified p27<sup>Kip1</sup>, was significantly diminished on G-CSF stimulation. Comparable results of assays with tyrosine-specific LAR-PTP and G-CSF strongly suggest that G-CSF stimulation mediates tyrosine dephosphorylation of p27<sup>Kip1</sup>. In view of these data, it is believable that the phosphorylation status of p27<sup>Kip1</sup> confers a different mobility. This could also explain the broad phosphotyrosine band of p27<sup>Kip1</sup> detected in our Western blots.

Investigating the interaction of p27<sup>Kip1</sup> with cdk2, we found that tyrosine phosphorylation of p27<sup>Kip1</sup> plays a crucial role in binding to cdk2 and cdk4. On G-CSF stimulation rapid tyrosine dephosphorylation of p27<sup>Kip1</sup> was accompanied by a dramatic release from cdk4, coinciding with a significantly increased binding to cdk2.

Although our results are restricted to NB4 cells stimulated by G-CSF, similar observations may be envisaged when assaying other cell line/growth factor combinations. A comparable growth factor-mediated



**Figure 4. Tyrosine phosphorylation of p27<sup>Kip1</sup> contributes to nuclear translocation.** (A) NIH/3T3 cells were incubated with BrdU for 4 hours. p27<sup>Kip1</sup> distribution and BrdU incorporation were detected with the appropriate antibodies. (B) NB4 cells (with or without stimulation with G-CSF for 60 minutes) were fractionated, lysate (100 μg) from cytosolic fraction C and nuclear fraction N was probed by Western blotting as indicated. Transcription factor PU.1 and Src kinase were used as markers for nuclear and cytosolic fraction, respectively.

switch in binding of p27<sup>Kip1</sup> to cyclin-dependent kinases has been reported earlier.<sup>22</sup> The authors suggested a model in which TGF-β modulates p27<sup>Kip1</sup> phosphorylation from its cyclin D1-bound assembly phospho form to an alternate form that binds tightly to inhibit cyclin E-cdk2. In their experiments, precipitated p27<sup>Kip1</sup> was treated with intestinal alkaline phosphatase and characterized by 2-dimensional IEF, and after phosphatase treatment, most of p27<sup>Kip1</sup> from the lysate of TGF-β-sensitive cells migrated at the highest IEF point, at pH 6.5. Likewise, in our experiments with G-CSF-treated NB4 cells, most

p27<sup>Kip1</sup> migrated as a spot with similar isoelectric point. However, by using intestinal alkaline phosphatase the authors were unable to provide information about the type of amino acid residue dephosphorylated upon TGF-β stimulation.<sup>22</sup> In contrast, in our studies tyrosine-specific LAR-PTP was used, which allowed the demonstration of tyrosine-specific phosphorylation on p27<sup>Kip1</sup>. Furthermore, we demonstrated that immunoprecipitated p27<sup>Kip1</sup> incubated with LAR phosphatase was in weak association with cdk4, whereas untreated protein largely bound to cdk4. This observation together with our studies on GST-p27<sup>Kip1</sup> fusion

**Table 1. Detection of apoptotic NIH/3T3 cells by fluorescence microscopy**

Transfected cells	p27 <sup>Kip1</sup> wt	p27 <sup>Kip1</sup> wt c-Abl-PP	p27 <sup>Kip1</sup> Y74F c-Abl-PP	p27 <sup>Kip1</sup> Y88/89F c-Abl-PP	p27 <sup>Kip1</sup> Y74/88/89F c-Abl-PP
<b>p27<sup>Kip1</sup> positive</b>					
Counted, no.	216	238	168	206	222
Apoptotic, no.	4	4	4	6	6
Apoptotic, %	1.85	1.68	2.38	2.91	2.70
<b>p27<sup>Kip1</sup> negative</b>					
Counted, no.	286	228	ND	ND	ND
Apoptotic, no.	6	4	ND	ND	ND
Apoptotic, %	2.09	1.75	ND	ND	ND

At least 2 independent transfection assays were scored.

p27<sup>Kip1</sup> positive indicates transfected cells overexpressing p27<sup>Kip1</sup>; p27<sup>Kip1</sup> negative, transfected cells without p27<sup>Kip1</sup> overexpression; ND, not determined.

proteins and transiently expressed p27<sup>Kip1</sup> strengthen the suggestion that tyrosine phosphorylation plays a crucial role for binding to cdk4.

To determine the tyrosine residues responsible for the binding preferences to cdk2 and cdk4, respectively, we performed assays with tyrosine to phenylalanine point mutations. Y88/89F and Y74/88/89F mutations blocked preferential binding of p27<sup>Kip1</sup> to cdk4. Furthermore, in contrast to p27<sup>Kip1</sup> wt and Y74F proteins, unphosphorylated Y88F or Y89F mutation displayed a stronger binding to cdk4 than their tyrosine-phosphorylated version. This divergence could be explained by loss of increased binding of cdk4 to phosphorylated p27<sup>Kip1</sup>. However, this would require unequal exposure of the different binding assays, which is unlikely because of standardized assay procedures. It is tempting to speculate that mutations of 2 adjacent tyrosine residues reveal divergent binding properties due to unknown steric effects. In our opinion, the data on binding of Y88/89F and Y74/88/89F to cdk4 are not disputed by the divergent behavior of Y88F and Y89F mutants.

Based on these studies we suggest that tyrosine residues at position 88 and 89 play a decisive role for binding to cdk4, whereas association with cdk2 appears not to be influenced by mutation of any tyrosine residue. This may be consistent with recent kinetic data on p27<sup>Kip1</sup> binding to the cdk2-cyclin A complex, which suggest a complex sequential mechanism regulated by segments of p27<sup>Kip1</sup> that are highly conserved within the family of cyclin-dependent kinase inhibitors.<sup>23</sup> However, kinetic experiments on binding to cdk4 were not performed in this study. We thus present here a novel binding mechanism of p27<sup>Kip1</sup> to cdk4 via phosphorylation of p27<sup>Kip1</sup> on Tyr88 and Tyr89.

Considering the regulation of cdk2 by cyclin E and cdk4 by cyclin D, we investigated the interaction of GST-p27<sup>Kip1</sup> wt with cyclin E and cyclin D. Neither unphosphorylated nor tyrosine-phosphorylated p27<sup>Kip1</sup> displayed interaction with cyclin E or cyclin D. In part, these findings did not surprise us because it is well documented that p27<sup>Kip1</sup> acts as potent inhibitor of cyclin E–dependent kinase cdk2,<sup>1</sup> resulting in a release of cyclin E from cdk2. According to our studies unphosphorylated protein binds preferentially to cdk2, whereas phosphorylated protein associates preferentially with cdk4. In this context, we expected interaction of tyrosine-phosphorylated GST-p27<sup>Kip1</sup> wt with cyclin D because p27<sup>Kip1</sup> is considered as positive regulator of cyclin D–dependent kinases like cdk4.<sup>1</sup> However, failure of interaction with cyclin D in our experimental settings mirrors recent data indicating that p27<sup>Kip1</sup> is not required for the formation of active cyclin D–cdk4 complexes.<sup>2</sup>

To investigate the biologic role of p27<sup>Kip1</sup> tyrosine phosphorylation we examined subcellular localization of transiently expressed p27<sup>Kip1</sup> in

NIH/3T3 cells. To ensure tyrosine phosphorylation of transient p27<sup>Kip1</sup> we cotransfected a plasmid containing the sequence of constitutive active c-Abl tyrosine kinase (Abl-PP). In this regard 2 arguments decided in favor of Abl-PP. First, c-Abl is generally located in the cytoplasm as well in the nucleus,<sup>24</sup> a prerequisite for studying the role of p27<sup>Kip1</sup> tyrosine phosphorylation on subcellular localization. Second, studies on the myelomonocytic leukemia cell line U937 attested interaction of p27<sup>Kip1</sup> with c-Abl (data not shown). We assume that NB4 cells reflect this interaction.

Our findings indicate that phosphorylation of both Tyr88 and Tyr89 contributes to nuclear translocation. Because there are no data on interference of both tyrosine residues with the nuclear localization signal (amino acid residues 153–166) documented,<sup>25</sup> it is tempting to speculate that phosphorylation of both tyrosine residues may interfere with nuclear export.

To relate the data on NIH/3T3 cells to untreated and G-CSF–stimulated NB4 cells we investigated subcellular distribution of p27<sup>Kip1</sup> by cell fractionation and observed a strong decline of p27<sup>Kip1</sup> in the nuclear fraction on G-CSF stimulation. Because our data document G-CSF–mediated tyrosine dephosphorylation of p27<sup>Kip1</sup>, nuclear translocation of tyrosine-phosphorylated protein must be considered the most likely explanation.

In parallel, we analyzed the influence of tyrosine point mutations on proliferation and observed independently of tyrosine phosphorylation a general blockade of proliferation of p27<sup>Kip1</sup> overexpressing cells. We expected this finding only in cells expressing unphosphorylated wt p27<sup>Kip1</sup>. According to the data presented, we suggest that unphosphorylated p27<sup>Kip1</sup> binds to cdk2 and, thus, inhibits proliferation. However, for cells expressing tyrosine-phosphorylated p27<sup>Kip1</sup>, it remains elusive whether nonphysiologic levels of transient overexpression may have overlapped possible nuances in proliferation that have been modulated by tyrosine phosphorylation. However, in regard to our data on NB4 cells we postulate a role for p27<sup>Kip1</sup> tyrosine phosphorylation in promoting the transforming potential of leukemic blasts blocked in granulopoiesis. Thus, G-CSF–mediated tyrosine dephosphorylation of p27<sup>Kip1</sup> may result in sequestration of cell cycle proteins in favor of cellular events like differentiation or migration. This could correlate with a recently published study indicating that differentiation of NB4 cells and other acute promyelocytic leukemia blasts from clinical samples treated with all-*trans*-retinoic acid (ATRA) was significantly enhanced by application of G-CSF.<sup>26</sup> It is well known that the clinical potential of ATRA in differentiation of acute promyelocytic leukemia blasts is intensified by myeloid growth factors like G-CSF.<sup>27,28</sup> However, the underlying molecular mechanisms induced by growth factors are unclear and will have to be investigated by further work.

## References

- Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev.* 1999;13:1501-1512.
- Bagui TK, Mohapatra S, Haura E, Pledger WJ. p27<sup>Kip1</sup> and p21<sup>Cip1</sup> are not required for the formation of active D cyclin-cdk4 complexes. *Mol Cell Biol.* 2003;23:7285-7290.
- Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. *Nat Med.* 2002;8:1153-1160.
- Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. *Nat Med.* 2002;8:1145-1152.
- Vigiletto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. *Nat Med.* 2002;8:1136-1144.
- Boehm M, Yoshimoto T, Crook MF, et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. *EMBO J.* 2002;21:3390-3401.
- Malek NP, Sundberg H, McGrew S, et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. *Nature.* 2001;413:323-327.
- Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. *Curr Biol.* 1999;9:661-664.
- Dimberg AI, Karlberg I, Nilsson K, Oberg FG. Ser-727/Tyr-701 phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. *Blood.* 2003;102:254-261.
- Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). *Cell.* 1996;85:721-732.
- Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. *Cell.* 1996;85:707-720.
- Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. *Genes Dev.* 2004;18:862-876.
- Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. *Genes Dev.* 2004;18:851-855.
- de Koning JP, Soede-Bobok AA, Ward AC, et al. STAT3-mediated differentiation and survival

- and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1). *Oncogene*. 2000;19:3290-3298.
15. Rane SG, Mangan JK, Amanullah A, et al. Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells. *Blood*. 2002;100:2753-2762.
  16. Tamura T, Simon E, Niemann H, Snoek GT, Bauer H. gp140v-fms molecules expressed at the surface of cells transformed by the McDonough strain of feline sarcoma virus are phosphorylated in tyrosine and serine. *Mol Cell Biol*. 1986;6:4745-4748.
  17. Moeller SJ, Head ED, Sheaff RJ. p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. *Mol Cell Biol*. 2003;23:3735-3752.
  18. Ward AC, Monkhouse JL, Hamilton JA, Csar XF. Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor. *Biochim Biophys Acta*. 1998;1448:70-76.
  19. Sugiyama Y, Tomoda K, Tanaka T, Arata Y, Yoneda-Kato N, Kato J. Direct binding of the signal-transducing adaptor Grb2 facilitates down-regulation of the cyclin-dependent kinase inhibitor p27Kip1. *J Biol Chem*. 2001;276:12084-12090.
  20. Hunter MG, Avalos BR. Phosphatidylinositol 3'-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. *J Immunol*. 1998;160:4979-4987.
  21. Barila D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. *Nat Genet*. 1998;18:280-282.
  22. Ciarallo S, Subramaniam V, Hung W, et al. Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. *Mol Cell Biol*. 2002;22:2993-3002.
  23. Lacy ER, Filippov I, Lewis WS, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. *Nat Struct Mol Biol*. 2004;11:358-364.
  24. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. *Trends Cell Biol*. 1999;9:179-186.
  25. Zeng Y, Hirano K, Hirano M, Nishimura J, Kanaide H. Minimal requirements for the nuclear localization of p27(Kip1), a cyclin-dependent kinase inhibitor. *Biochem Biophys Res Commun*. 2000;274:37-42.
  26. Matsui W, Smith BD, Vala M, et al. Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. *Br J Haematol*. 2005;128:853-862.
  27. Jansen JH, de Ridder MC, Geertsma WM, et al. Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. *Blood*. 1999;94:39-45.
  28. Higuchi T, Kizaki M, Omine M. Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. *Leuk Res*. 2004;28:525-532.